The subgroup analysis of patients with advanced NSCLC (Tumor stage III-IV) showed that, NSCLC patients with p53 negative expression were more sensitive to platinum chemotherapy than those with p53 positive expression, the pooled OR = 1.93 (95%CI: 1.27∼2.93, P < .01). This evidence concerns the gene TP53 and non-small cell lung carcinoma.